Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 3/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | STK10 | O94804 | 1/20 | 0.30 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10195176 | 0.89 | FFAR1 (0.40) | HTR2AKCNH2SLC6A4TBXA2RNR3C1 | |
| SCHEMBL10195289 | 0.89 | EGLN2 (0.33) | PGREGLN2EGLN1 | |
| SCHEMBL10195177 | 0.88 | AR (0.39) | AR | |
| SCHEMBL10195084 | 0.88 | MAPK14 (0.42) | HTR2AKCNH2SLC6A4MAPK14AR | |
| SCHEMBL10195183 | 0.87 | PGR (0.37) | PGR | |
| SCHEMBL416035 | 0.87 | TBXA2R (0.32) | HTR2AKCNH2SLC6A4TBXA2RNR3C1 | |
| SCHEMBL16181150 | 0.87 | PPARG (0.34) | MAPK14BRD4 | |
| SCHEMBL10195667 | 0.86 | TBXA2R (0.31) | HTR2AKCNH2SLC6A4TBXA2RGPR119 | |
| SCHEMBL10195083 | 0.86 | SLC6A4 (0.38) | HTR2AKCNH2SLC6A4MAPK14BRD4 | |
| SCHEMBL10195073 | 0.86 | MAPK14 (0.33) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387569-B1 | HERBCIDES | SYNGENTA LTD (GB) | 2016-06-15 | — | — | EP | disclosed |
| US-20140378305-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378305-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | disclosed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | disclosed |
| US-20120021907-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021907-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010081755-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378305-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | HTR2A 1192/4885KCNH2 1267/4885SLC6A4 1501/4885 |
| US-20120021907-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | HTR2A 1320/4885KCNH2 1805/4885SLC6A4 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.